TLRsignaling on pDCs can be used to induce type I IFNs and possibly protect DCsfrom tumor-derived inhibitory factors (such as VEGFβ or IL-10), as well as supportT-cell survival, therefore, improving vaccination efficacy [112, 142–147]. The gene discussed is IL10; the disease is neoplasm.